Who makes AG019 - High Dose?

AG019 - High Dose is developed by Precigen Actobio T1D, LLC.

What development phase is AG019 - High Dose in?

AG019 - High Dose is in Phase 1.

What are the side effects of AG019 - High Dose?

Common side effects include Dyspepsia, Anaemia, Eosinophilia, Erythropenia, Iron deficiency anaemia, Leukopenia.

Last reviewed 2026-04-20 · How we verify

AG019 - High Dose

Precigen Actobio T1D, LLC · Phase 1 active Biologic Quality 15/100

At a glance

Generic name	AG019 - High Dose
Sponsor	Precigen Actobio T1D, LLC
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Dyspepsia
Anaemia
Eosinophilia
Erythropenia
Iron deficiency anaemia
Leukopenia
Lymphadenopathy
Lymphopenia
Microcytic anaemia
Neutropenia
Palpitations
Sinus bradycardia

Key clinical trials

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AG019 - High Dose CI brief — competitive landscape report
AG019 - High Dose updates RSS · CI watch RSS
Precigen Actobio T1D, LLC portfolio CI